Recursion Announces CEO Transition to Propel Next Growth Phase
- bancheta6
- Nov 6
- 1 min read
Salt Lake City, UT, November 5, 2025 (Globe Newswire) -- Recursion (NASDAQ: RXRX), a leading TechBio company integrating AI, biology, and chemistry, announced a planned leadership transition effective January 1, 2026. Co-founder and current CEO Chris Gibson will assume the role of Chairman of the Board, while Najat Khan, Ph.D., currently Chief R&D and Commercial Officer, will become CEO and President.
The move aims to ensure continuity as Recursion advances its platform and pipeline of transformative medicines. Dr. Khan, who joined Recursion in 2024, played a key role in the company’s merger with Exscientia and expansion of the Recursion OS 2.0 platform. Before Recursion, she held senior R&D leadership roles at Johnson & Johnson and BCG.
Read full article here.
Comments